Johnson & Johnson Stock: New Investments in Cancer and Psychiatry - ad-hoc-news.de
Article excerpt
Highlighted: the sentence this signal was extracted from
Johnson & Johnson is expanding its strategic reach in oncology and psychiatry. According to Yahoo Finance on Thursday, November 12, the healthcare group agreed to an investment in Francis Medical while also leading a 100 million US dollar financing round for Delix Therapeutics. Francis Medical is developing Vanquish, a minimally invasive device for the treatment of prostate cancer. The investment complements Johnson & Johnson's existing activities in this disease area, which also include the bispecific agents pasritamig and JNJ-9401. Vanquish targets localized prostate cancer, while the drug programs address advanced diseases. The company is thus further broadening its activities from local treatment to systemic therapy. For investors, the transaction is primarily a strategic addition with a longer time horizon. The device is still in the development phase, so the investment will not result in a significant revenue contribution in the short term. Clinical progress, regulatory steps, and subsequent healthcare reimbursement will be decisive. The financing round at Delix Therapeutics, led by Johnson & Johnson, is intended to fund clinical programs for psychedelically inspired depression therapies. According to the company, the drug candidates aim to rely on new treatment approaches without triggering the hallucinations typical of classic psychedelics. The investment thus...
Keep reading with a free account
The rest of this article, and every signal for Johnson & Johnson, is in your free account.
